mouse breast cancer cell line py8119 (ATCC)
Structured Review

Mouse Breast Cancer Cell Line Py8119, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 123 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse breast cancer cell line py8119/product/ATCC
Average 97 stars, based on 123 article reviews
Images
1) Product Images from "Paclitaxel drives TREM2 + macrophage expansion underlying its inferior therapeutic efficacy compared to Nab-paclitaxel"
Article Title: Paclitaxel drives TREM2 + macrophage expansion underlying its inferior therapeutic efficacy compared to Nab-paclitaxel
Journal: Nature Communications
doi: 10.1038/s41467-026-69060-5
Figure Legend Snippet: a Representative immunofluorescence staining of tissues from patients with and without lung metastases. b Quantification of TREM2-expressing macrophages in tissues from patients with and without lung metastases ( n = 5 patients per group). c Schematic of the experimental design in 4T1-Luc breast-tumor-bearing mice treated with DMSO or PTX. Created in BioRender. Xing, Y. (2026) https://BioRender.com/nsp747p d Representative in vivo bioluminescence images of mice that received the indicated treatments ( n = 5 mice per group). e Representative bright-field images (left) and hematoxylin and eosin (H&E) staining (right) of lungs from mice injected orthotopically with 4T1-Luc cells and treated as described in ( c ) ( n = 5 mice per group). f Quantification (right) of the total numbers of lung-surface metastases ( n = 6 mice per group). g Representative flow cytometry analysis showing a histogram (left) and quantification (right) of the proportion of TREM2-expressing macrophages in tumors ( n = 3 mice per group). h Representative immunofluorescence staining of tumors in mice that received the indicated treatments. i Schematic of Nab-PTX treatment in Py8119 breast tumor-bearing mice. Mice were intraperitoneally injected with DMSO, PTX, PBS, or Nab-PTX at the indicated times. Created in BioRender. Xing, Y. (2026) https://BioRender.com/nsp747p j Photographs (left) of tumors in mice that received the indicated treatments on day 14. Tumor weights (right) of mice that received the indicated treatments ( n = 6 mice per group). k Tumor volumes (right) of mice that received the indicated treatments ( n = 6 mice per group). l Representative bright-field images (left) of lungs from mice that received the indicated treatments. Quantification of the total numbers of lung-surface metastases is shown (right) ( n = 6 mice per group). m Representative H&E-stained images of lungs from mice that received the indicated treatments. n , o Representative flow cytometric analysis of pseudo-color plots ( n ) and quantification ( o ) showing the proportion of TREM2-expressing macrophages in tumors ( n = 4 mice per group). Data are shown as means ± S.D. and were analyzed by two-sided unpaired Student’s t test ( b , f and g ), two-sided one-way ANOVA followed by Tukey’s test ( j , l and o ) and two-sided two-way ANOVA followed by Tukey’s test ( k ). Source data are provided as a Source Data file.
Techniques Used: Immunofluorescence, Staining, Expressing, In Vivo, Injection, Flow Cytometry
Figure Legend Snippet: a Schematic of the experimental design. Trem2 +/+ and Trem2 −/− mice were orthotopically injected with Py8119 cells and treated with DMSO or PTX, respectively. Created in BioRender. Xing, Y. (2026) https://BioRender.com/nsp747p b Photographs of representative tumors from mice that received the indicated treatments on day 14. c Tumor growth curves (left) and tumor weights (right) of Py8119 tumors in mice that received the indicated treatments ( n = 6 mice per group). d Representative bright-field images (left) of lungs from Py8119 cell-bearing mice that received the indicated treatments. Quantification of the total number of lung-surface metastases is shown (right) ( n = 6 mice per group). e Representative H&E-stained images of lungs from mice. f Representative flow cytometric analysis of histograms showing the proportion of TREM2-expressing macrophages in tumors. g Quantification of flow cytometric analysis showing the proportion of TREM2-expressing macrophages in tumors ( n = 3 mice per group). h Representative flow cytometric analysis of pseudo-color plots showing the proportion of TREM2-expressing macrophages in the PB of mice ( n = 3 mice per group). i Schematic of the experimental design. Trem2 -/- mice were co-injected orthotopically with Py8119 cells and BMDMs. Created in BioRender. Xing, Y. (2026) https://BioRender.com/nsp747p j Photographs of representative tumors from Trem2 -/- mice that received the indicated treatments on day 17. k Tumor growth curves (left) and tumor weights (right) of Py8119 tumors in Trem2 -/- mice ( n = 6 mice per group). l Representative bright-field images (left) of lungs from Trem2 -/- mice that received the indicated inoculations. Quantification of the total number of lung-surface metastases is shown (right) ( n = 6 mice per group). Data are shown as means ± S.D. and were analyzed by two-sided unpaired Student’s t test ( g ), two-sided one-way ANOVA followed by Tukey’s test ( c , d , k and l ) and two-sided two-way ANOVA followed by Tukey’s test ( c and k ). Source data are provided as a Source Data file.
Techniques Used: Injection, Staining, Expressing
Figure Legend Snippet: a Schematic of ASO treatment in Py8119 breast-tumor-bearing mice. Mice were intraperitoneally injected with DMSO or PTX and intratumorally injected with inactive ASOs or Trem2 ASOs at the indicated times. Created in BioRender. Xing, Y. (2026) https://BioRender.com/nsp747p b Photographs (left) and tumor weights (right) of representative tumors in mice that received the indicated treatments on day 14. c Tumor growth curves of mice that received the indicated treatments ( n = 6 mice per group). d Representative bright-field images of lungs from mice that received the indicated treatments. e Representative H&E-stained images (left) of lungs from mice that received the indicated treatments. Quantification of the total number of lung-surface metastases is shown (right) ( n = 6 mice per group). f Survival curves of Py8119 breast tumor-bearing mice that received the indicated treatments ( n = 6 mice per group). Data are shown as means ± S.D. and were analyzed by two-sided one-way ANOVA followed by Tukey’s test ( b and e ), two-way ANOVA followed by Tukey’s test ( c ) and log-rank test ( f ). Source data are provided as a Source Data file.
Techniques Used: Injection, Staining
Figure Legend Snippet: a Schematic of the experimental setup with THP1 or Raw264.7 cells with indicated treatment. Created in BioRender. Xing, Y. (2026) https://BioRender.com/nsp747p b Quantification of proportion of TREM2 in THP1 and Raw264.7 cells with PTX. n = 3 biological independent samples. c Western blot of THP1 and Raw264.7 cells with indicated treatments. The experiment was independently repeated three times with similar results. d Schematic of the experimental strategy. CM was collected from tumor cells with the indicated treatment. TREM2 expression in macrophages incubated with the CM was assessed. Created in BioRender. Xing, Y. (2026) https://BioRender.com/nsp747p e Quantification of proportion of TREM2 in THP1 incubated with CM of BT549 cells, SUM159 cells and MDA-MB-231 cells treated with PTX, in BMDM incubated with CM of Py8119 treated with PTX, in Raw264.7 incubated with CM from 4T1 and Py8119 cells treated with PTX, respectively. n = 3 biological independent samples. f Western blot analysis of TREM2 and related proteins in THP1, BMDMs, and Raw264.7 cells incubated with CM from BT549, SUM159, Py8119, and 4T1 cells, respectively. The experiment was independently repeated three times with similar results. g Representative immunofluorescence staining of THP1 cells incubated with BT549 CM. n = 3 biological independent samples. h Quantification of proportion of TREM2 in THP1 incubated with CM from BT549, SUM159, and MDA-MB-231 cells treated with Nab-PTX, respectively. n = 3 biological independent samples. i Quantification of the proportion of TREM2 in BMDM incubated with CM of Py8119 treated with Nab-PTX. n = 3 biological independent samples. j Cytokine array analysis of CM from BT549 cells treated indicated treatment. k Western blot analysis of the indicated proteins in Raw264.7 cells and BMDMs treated with recombinant FGF2. The experiment was independently repeated three times with similar results. l Quantification of the proportion of TREM2 in Raw264.7 cells and BMDMs treated with recombinant FGF2. n = 3 biological independent samples. m Schematic of the experimental strategy. CM was collected from tumor cells with the indicated treatment, and then pretreatment using an FGF2 neutralizing antibody. TREM2 expression in macrophages incubated with the CM was assessed. Created in BioRender. Xing, Y. (2026) https://BioRender.com/nsp747p n Western blot analysis of the indicated proteins in Raw264.7 and BMDMs incubated with the indicated CM. The experiment was independently repeated three times with similar results. o Quantification of the proportion of TREM2 in Raw264.7 and BMDMs incubated with the indicated CM. n = 3 biological independent samples. p Representative multiplex immunofluorescence staining of CD68, TREM2 and FGF2 in tumors treated with PTX or Nab-PTX ( n = 3 mice per group). The experiment was independently repeated three times with similar results. Data are shown as means ± S.D. and were analyzed by two-sided unpaired Student’s t test ( b , e , h and i ) and two-sided one-way ANOVA followed by Tukey’s test ( l and o ). Source data are provided as a Source Data file.
Techniques Used: Western Blot, Expressing, Incubation, Immunofluorescence, Staining, Recombinant, Multiplex Assay
Figure Legend Snippet: a Overlap of RNA-seq ( n = 3) and PROMO public database analyses to predict transcription factors regulating TREM2 expression. b Correlations between FGF2 and ATF3 expression in breast cancer using TCGA databases. c qPCR analysis of Atf3 expression in the indicated cells. n = 4 (DMSO and PTX) or 3 (PBS and Nab-PTX) biological independent samples. d Western blot analysis of the indicated proteins in Py8119 cells transfected with ATF3-expressing or control vectors. The experiment was independently repeated three times with similar results. e qPCR analysis of Fgf2 expression in Py8119 cells transfected with Atf3 -expressing or control vectors. n = 3 biological independent samples. f Luciferase activity in HEK293T cells transfected with the indicated reporters and Atf3 -expressing or control vectors. n = 3 biological independent samples. g Abundance of Atf3 bound to the Trem2 promoter in Py8119 cells, as assessed by ChIP-qPCR. n = 3 biological independent samples. h ATAC-seq tracks showing the chromatin accessibility in the ATF3 loci for BT549 cells treated by PTX or Nab-PTX. n = 2 samples per group. Data are shown as means ± S.D. and were analyzed by two-sided unpaired Student’s t test ( c, e and f ) and two-sided two-way ANOVA followed by Šídák’s test ( g ). Source data are provided as a Source Data file.
Techniques Used: RNA Sequencing, Expressing, Western Blot, Transfection, Control, Luciferase, Activity Assay, ChIP-qPCR
Figure Legend Snippet: a Overlap of GeneCards and EDCODE public databases analyses to predict transcription factors that regulate TREM2. b Western blot analysis of the indicated proteins in BMDMs and Raw264.7 cells incubated with FGF2 (left) and with CM from Py8119 cells treated with PTX (right). The experiment was independently repeated three times with similar results. c Western blot analysis of the indicated proteins in Raw264.7 cells incubated with the indicated treatment. The experiment was independently repeated three times with similar results. d qPCR analysis of Trem2 expression in BMDMs transfected with Egr1 -expressing vectors. n = 3 biological independent samples. e Western blot analysis of TREM2 expression in BMDMs transfected with Egr1 -expressing vectors. The experiment was independently repeated three times with similar results. f Luciferase activity of HEK293T cells transfected with the indicated reporters and EGR1 -expressing or control vectors. n = 3 biological independent samples. g Abundance of EGR1 bound to the TREM2 promoter in BMDMs assessed by ChIP-qPCR. n = 3 biological independent samples. h Schematic of the Transwell assay. The first CM was collected from tumor cells with indicated treatment, and the second CM was collected from macrophages incubated with the first CM. The migration and invasion capabilities of macrophages incubated with the first CM were assessed. Created in BioRender. Xing, Y. (2026) https://BioRender.com/nsp747p i Quantification of migration and invasion of Py8119 cells induced by BMDM CM incubated with CM from Py8119 cells treated with PTX, and BT549, SUM159, and MDA-MB-231 cells induced by THP1 CM incubated with CM from BT549, SUM159, and MDA-MB-231 cells treated with PTX (left) or Nab-PTX (right), respectively. n = 5 biological independent samples. j Cytokine array analysis of CM from BMDMs with or without TREM2. k Quantification of migration and invasion of Py8119 cells incubated with indicated proteins. n = 3 biological independent samples. l Quantification of migration and invasion of Py8119 cells induced by CM from BMDMs ( Trem2 +/+ ) with CDE-096. n = 3 biological independent samples. m Western blot analysis of EMT- stimulating proteins in BMDMs incubated with indicated proteins. The experiment was independently repeated three times with similar results. n Schematic illustration showing that FGF2 promotes ERK1/2 phosphorylation to upregulate EGR1, which increases TREM2 expression in macrophages. Upregulated TREM2 enhances the secretion of Serpin E1, HGF, CCL3, and CXCL2 from macrophages to tumor cells, facilitating tumor metastasis via EMT. Created in BioRender. Xing, Y. (2026) https://BioRender.com/nsp747p . Data are shown as means ± S.D. and were analyzed by two-sided unpaired Student’s t test ( d, f, i and l ), two-sided one-way ANOVA followed by Tukey’s test ( k ) and two-sided two-way ANOVA followed by Šídák’s test ( g ). Source data are provided as a Source Data file.
Techniques Used: Western Blot, Incubation, Expressing, Transfection, Luciferase, Activity Assay, Control, ChIP-qPCR, Transwell Assay, Migration, Phospho-proteomics